Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics (Nasdaq: XLO) announced on Oct 2, 2025 that effective Oct 1, 2025 it granted non‑qualified stock options to purchase 26,000 shares to three new employees under its 2022 Inducement Stock Incentive Plan.
The options have an exercise price of $0.8326 (equal to the closing price on Oct 1, 2025), a 10‑year term, and vest 25% after 1 year with the remaining 75% vesting in 36 equal monthly installments, subject to continued service. Grants were made as inducements in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the plan and option agreement terms.
Xilio Therapeutics (Nasdaq: XLO) ha annunciato il 2 ottobre 2025 che, con effetto dal 1 ottobre 2025, ha concesso opzioni azionarie non qualificate per l'acquisto di 26.000 azioni a tre nuovi dipendenti nell'ambito del 2022 Inducement Stock Incentive Plan.
Le opzioni hanno un prezzo di esercizio di $0,8326 (uguale al prezzo di chiusura del 1 ottobre 2025), una durata di 10 anni e maturano al 25% dopo 1 anno con il 75% restante che matura in 36 rate mensili uguali, soggette a continuativo servizio. Le assegnazioni sono state effettuate come induzioni in conformità con la Nasdaq Listing Rule 5635(c)(4) e sono soggette ai termini del piano e dell'accordo sull'opzione.
Xilio Therapeutics (Nasdaq: XLO) anunció el 2 de octubre de 2025 que, con efecto a partir del 1 de octubre de 2025, otorgó opciones de compra de acciones no calificadas para adquirir 26.000 acciones a tres nuevos empleados bajo su 2022 Inducement Stock Incentive Plan.
Las opciones tienen un precio de ejercicio de $0,8326 (equivalente al precio de cierre del 1 de octubre de 2025), una vigencia de 10 años y se consolidan en un 25% tras 1 año con el 75% restante consolidándose en 36 cuotas mensuales iguales, sujeto a la continuidad del servicio. Las adjudicaciones se realizaron como incentivos de acuerdo con la Nasdaq Listing Rule 5635(c)(4) y están sujetas a los términos del plan y del acuerdo de opciones.
Xilio Therapeutics (Nasdaq: XLO)는 2025년 10월 2일에 2025년 10월 1일부로 비자격 주식매수선택권을 세 명의 신규 직원에게 부여했다고 발표했습니다. 이는 2022 Inducement Stock Incentive Plan에 따른 것입니다.
옵션의 행사가는 $0.8326이며(2025년 10월 1일 종가와 동일), 만기는 10년이고 1년 후 25%가 확정되며 남은 75%는 36개월의 등분 월별 행사로 확정됩니다(지속 근무 조건 충족 시). 보상은 Nasdaq Listing Rule 5635(c)(4)에 따라 유인책(inducement)으로 수여되었으며 계획 및 옵션 계약의 조건에 따릅니다.
Xilio Therapeutics (Nasdaq : XLO) a annoncé le 2 octobre 2025 que, à compter du 1er octobre 2025, elle a accordé des stock options non qualifiées d'achat de 26 000 actions à trois nouveaux employés dans le cadre de son 2022 Inducement Stock Incentive Plan.
Les options ont un prix d'exercice de 0,8326 $ (identique au cours de clôture au 1er octobre 2025), une durée de 10 ans, et elles se vestent à 25% après 1 an avec les 75% restants vesting en 36 versements mensuels égaux, sous réserve d'un service continu. Les attributions ont été faites à titre d'incitation conformément à la Nasdaq Listing Rule 5635(c)(4) et sont soumises aux termes du plan et de l'accord d'option.
Xilio Therapeutics (Nasdaq: XLO) gab am 2. Oktober 2025 bekannt, dass mit Wirkung zum 1. Oktober 2025 nicht qualifizierte Aktienoptionen zum Kauf von 26.000 Aktien an drei neue Mitarbeitende im Rahmen ihres 2022 Inducement Stock Incentive Plan gewährt wurden.
Die Optionen haben einen Ausübungspreis von 0,8326 US-Dollar (entspricht dem Schlusskurs vom 1. Oktober 2025), eine Laufzeit von 10 Jahren und vesten zu 25% nach 1 Jahr mit dem restlichen 75%, der in 36 gleichen monatlichen Raten vestet, vorbehaltlich fortgesetzter Dienstzeit. Die Zuteilungen wurden als Anreize gemäß der Nasdaq Listing Rule 5635(c)(4) vorgenommen und unterliegen den Bedingungen des Plans und der Optionsvereinbarung.
Xilio Therapeutics (ناسداك: XLO) أعلنت في 2 أكتوبر 2025 أن بدءًا من 1 أكتوبر 2025 قد منحت خيارات أسهم غير مؤهلة لشراء 26,000 سهماً لثلاثة موظفين جدد بموجب خطة حوافز الأسهم لعام 2022.
للدًّور هذه الخيارات سعر ممارسة قدره 0.8326 دولار (يساوي سعر الإغلاق في 1 أكتوبر 2025)، ومدى صلاحية 10 سنوات، وتكتسب حقوق الملكية 25% بعد عام واحد، و75% المتبقي يكتسب عبر 36 دفعة شهرية متساوية، رهناً باستمرار الخدمة. أُقرت المنح كحوافز وفقاً لـ قواعد إدراج ناسداك 5635(c)(4) وتخضع لشروط الخطة واتفاقية الخيار.
Xilio Therapeutics (Nasdaq: XLO) 宣布于 2025年10月2日，自 2025年10月1日起生效，向三名新员工授予 26,000 股购买非合格股票期权，纳入其 2022 Inducement Stock Incentive Plan。
期权的 行权价为 $0.8326（等于 2025年10月1日 的收盘价），期限为 10年，在 1年后 行权 25%，其余 75% 将在 36 个月内按等额月度分期完成 vesting，前提是持续在职。此次授予符合 Nasdaq Listing Rule 5635(c)(4) 的诱导性原则，并受计划及期权协议条款的约束。
- None.
- None.
WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective October 1, 2025, the company granted non-qualified stock options to purchase 26,000 shares of its common stock to three new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.
The stock options have an exercise price of
The stock options are subject to the terms and conditions of Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreement covering the grant and were made as an inducement material to the individual entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated, or masked, immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary platform to advance a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).
Investor Contact
investors@xiliotx.com
Media Contact
Josie Butler, 1AB
josie@1abmedia.com
FAQ
What did Xilio Therapeutics (XLO) announce on Oct 2, 2025?
What is the exercise price and term of the XLO inducement options?
How do the XLO inducement options vest?
Why were the stock options granted under Nasdaq Listing Rule 5635(c)(4)?
How many employees received inducement option grants from XLO?
Are the XLO options subject to additional terms or agreements?
